Alnylam slides as valuation worries persist after Jefferies downgrade and target cut
Alnylam Pharmaceuticals (ALNY) fell 3.30% to $308.82 as investors continued to de-risk after Jefferies downgraded the stock to Hold and slashed its price target to $330, citing valuation concerns. With no new company press release dated April 18, 2026, the move looks driven by the lingering analyst reset and profit-taking after recent strength.
1. What’s moving the stock
Alnylam Pharmaceuticals shares traded lower Friday as the market continued to digest a recent valuation-driven reset. The key near-term catalyst has been Jefferies’ downgrade of ALNY to Hold from Buy alongside a steep price-target cut to $330, framing the stock as “priced to perfection” and increasing sensitivity to any execution or guidance disappointment. (247wallst.com)
2. Why the pressure is showing up now
With no fresh Alnylam press release dated April 18, 2026, traders appear to be extending the post-downgrade derisking and profit-taking cycle rather than reacting to a new fundamental headline. The company’s most recent investor-site update was an April 16 announcement of an upcoming webcast conference call to discuss first-quarter 2026 financial results, keeping attention on the next earnings checkpoint. (investors.alnylam.com)
3. What to watch next
Near-term focus shifts to the first-quarter 2026 results call and any updates on commercial momentum across the TTR franchise, including pricing and demand trends that could influence 2026 expectations. Any additional analyst target changes or commentary ahead of the quarter could amplify volatility given the stock’s elevated starting valuation after its strong multiyear run. (investors.alnylam.com)